- Global Pharma News & Resources

BioConsortia Appoints Nancy Vosnidou IP & Portfolio Strategist

BioConsortia expanding patent portfolio of novel metabolites, natural and gene-editing microbes for biopesticides and nitrogen fixation

DAVIS, Calif.--(BUSINESS WIRE)--As BioConsortia continues its discovery and development of powerful microbes with unique modes of action and innovates further into gene editing for microbial biopesticides and nitrogen fixation, we are pleased to announce that Nancy Vosnidou will join the BioConsortia team in the newly created position of IP & Portfolio Strategist.

Nancy brings deep experience in patent portfolio development and strategy, as well as competitive intelligence. Most recently, Nancy managed the CRISPR and molecular engineering IP portfolios for Corteva, a multinational ag tech company, with previous IP experience in pharmaceutical biologicals, ag microbials at a unicorn startup, and transgenic crop development with another of the big 5 agricultural companies. Nancy holds a PhD in Biophysics, MS in Pathology/Clinical Chemistry, and BS in Biology from University of Missouri.

“We are excited to have someone with this depth of experience, knowledge and skill join our team,” said Christina Huben, Senior Vice President Operations & Administration. “Creating and protecting our IP is a key part of BioConsortia’s value proposition as a startup.”

BioConsortia recently announced a deal to develop and commercialize nitrogen fixing microbes for non-legume crops with Mosaic, the $9 billion revenue fertilizer company, and has moved into ground-breaking areas of research for natural and gene edited microbial products that are superior in efficacy, high in consistency, beneficial for farming and friendly toward the environment, its natural resources and habitats.

“These are exciting times at BioConsortia. We have built a world-class team, which is doing great research, and we continue to move from strength to strength. Nancy is a very talented addition to this winning team,” said Marcus Meadows-Smith, CEO – BioConsortia, Inc..

About BioConsortia

BioConsortia, Inc. is developing effective microbial solutions that enhance plant phenotypes and increase crop yields. We are pioneering the use of directed selection in identifying teams of microbes - working like plant breeders and selecting plants based on targeted characteristics, then isolating the associated microbial community. Our unique, patented Advanced Microbial Selection (AMS) process enriches the crop microbiome, allowing us to identify organisms that influence the expression of beneficial traits in plants. We use a powerful toolkit including multi-trait screening, colonization technologies, microbiome analysis, genomics, and gene editing. As a result, we have a remarkable hit rate of high quality leads, some with novel patent-pending metabolites, and an extraordinarily deep pipeline of products in development.

BioConsortia focused on launching products with superior efficacy, higher consistency, and breakthrough technologies in 3 key areas:

1) Biopesticides: a pipeline of biofungicides and nematicides with superior efficacy
2) Biostimulants: growth promoting products that further increase yields in standard, high-yielding, as well as stressed, agronomic conditions
3) Nitrogen-fixation and fertilizer use efficiency: developing products for major non-legume row crops (such as corn and wheat)

Our products are foliar, drench, seed treatment, in-furrow and granule products for a wide range of crops.

For inquiries and further information, please contact


Jon Amdursky
BioConsortia - Marketing Communications

Editor Details

  • Company:
    • Businesswire
Last Updated: 06-May-2021